Univariate analysis of peripheral neurotoxicity induced by oxaliplatin chemotherapy in patients with colorectal cancer and its prevention and treatment strategies
10.3760/cma.j.cn341190-20210621-00702
- VernacularTitle:结直肠癌患者奥沙利铂化疗致外周神经毒性单因素分析及其防治策略
- Author:
Xinyan YU
1
;
Man LI
;
Liping XIANG
;
Jialan XU
Author Information
1. 中国科学院大学附属肿瘤医院 浙江省肿瘤医院腹部肿瘤内科109病区，杭州 310022
- Keywords:
Colorectal neoplasms;
Platinum compound;
Anti-tumor combined chemotherapy regimen;
Hypoesthesia;
Analysis of influencing factors;
Drug-related side effects
- From:
Chinese Journal of Primary Medicine and Pharmacy
2023;30(1):2-6
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the related factors of neurotoxicity induced by oxaliplatin chemotherapy in patients with colorectal cancer and its prevention and treatment strategies.Methods:A total of 300 patients with colorectal cancer treated with oxaliplatin in Zhejiang Cancer Hospital from January 2018 to December 2020 were randomly selected for baseline collection using the convenience sampling method. The occurrence of oxaliplatin-induced peripheral neurotoxicity (OIPN) was statistically analyzed. The factors that affect the occurrence of OIPN were analyzed using univariate analysis.Results:There was a significant difference in OIPN score between patients of different genders, between patients who had different education levels, between patients who had different occupations, and between patients who lived in different long-term residence places ( t = 7.29, 3.39, 2.53, 18.11, all P < 0.05). There was no significant difference in OIPN score between patients adhering to different religion's beliefs, between patients married and not, between patients who lived with and without members, between patients who paid medical costs and not, and between patients who had a previous history of smoking and not ( t = 3.25, 0.37, 0.69, 2.39, 0.15, all P > 0.05). There was a significant difference in OIPN score between patients with different tumor-node-metastasis stages, between patients who received medication via different administration routes, and between patients who received different times of oxaliplatin administration ( t = 8.40, 3.34, 3.49, all P < 0.05). Conclusion:Medical staff should pay attention to the occurrence of OIPN in patients with colorectal cancer treated with oxaliplatin, focus on the patient's factors related to the disease, and take correct and effective coping strategies promptly to reduce the adverse reactions, improve the quality of life, and ensure the therapeutic effect.
